Adebrelimab Neoadjuvant Treatment for Resectable ESCC

NCT07388095 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

ESCC

Interventions

DRUG: Adebrelimab (PD-L1 inhibitor)

Sponsor

Tianjin Medical University Cancer Institute and Hospital